Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAN2401 Phase 1 in Early AD
NCT02094729Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 14 weeks. Started Sep 2013; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02094729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094729.